We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Trial results come a month after UK terminated a contract with the French company
Bullish projections show mRNA jab producers could generate more than $90bn in sales next year
Head of Royal College of Pathologists says NHS backlog cannot be cleared without more investment in his field
Deaths and hospital admissions remain stubbornly high in Britain as the continent reports record lows
Freight costs now at 10 times pre-pandemic levels
Seasonal shortages are a spur to manufacturers to invest in capacity
An estimated 43,000 people given incorrect negative PCR results, says government health agency
Demonstrators take to streets on day mandatory measure for workers is introduced
Company’s pandemic share price gains are dwarfed by those of its rivals despite its jab’s stunning success
Panel recommends third jabs for vulnerable people in step towards expanding US rollout of extra doses
Deaths from TB increase for first time in over a decade despite confirmed cases falling
Erdogan wants to buy more F16s while planning to order second Russian air defence system
Manufacturing hub for global brands struggles to find staff to resume normal operations
Personalised cancer treatments are among those being developed using a technology once distrusted by big pharma
Japanese pharma company says Medicago’s product will be cheaper to make and easier to transport
IMF warns uneven pace of immunisation raises risks of economic scarring
German biotech had suffered disappointing results after initial excitement
Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments
Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people
Experts urge caution despite Delta wave slowdown amid concerns over new variants and vaccine hesitancy
Advances by Merck and AstraZeneca raise hopes of bringing more treatments to market
Imperfect figures mean many countries do not know how many residents have been vaccinated
Former IMF official said the divisions have undermined Kristalina Georgieva’s ability to lead
Researchers are hailing a breakthrough in personalised treatments for mental illness that could be used for other conditions
September data fall short of expectations and suggest rebound in growth is slowing
International Edition
